Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents
Artificial DNA: PNA & XNA · 2011
DOI: 10.4161/adna.17731 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial DNA: PNA & XNA, 2011. Verfasst von Adrian G Torres und 2 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Council, Laboratory of Molecular Biology, Cambridge, UK. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Council, Laboratory of Molecular Biology, Cambridge, UK.
Förderung
- Medical Research Council
Zitieren
APA
Torres, A. G., Threlfall, R. N., & Gait, M. J. (2011). Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents. Artificial DNA: PNA & XNA. https://doi.org/10.4161/adna.17731
Vancouver
Torres AG, Threlfall RN, Gait MJ. Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents. Artificial DNA: PNA & XNA. 2011. doi:10.4161/adna.17731
BibTeX
@article{Torres2011,
author = {Torres, Adrian G and Threlfall, Richard N and Gait, Michael J},
title = {Potent and sustained cellular inhibition of miR-122 by lysine-derivatized peptide nucleic acids (PNA) and phosphorothioate locked nucleic acid (LNA)/2'-O-methyl (OMe) mixmer anti-miRs in the absence of transfection agents},
journal = {Artificial DNA: PNA & XNA},
year = {2011},
doi = {10.4161/adna.17731}
}
EUVIMED